Literature DB >> 17669305

[Capecitabine-induced hyperpigmentation].

C Vázquez-Bayo1, A L Rodríguez-Bujaldón, R Jiménez-Puya, M Galán-Gutiérrez, J C Moreno-Giménez.   

Abstract

Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesias and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669305

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  4 in total

1.  Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.

Authors:  Michael M Vickers; Jacob C Easaw
Journal:  J Gastrointest Cancer       Date:  2009-05-14

2.  Chemotherapy and skin reactions.

Authors:  Gabriella Fabbrocini; Norma Cameli; Maria Concetta Romano; Maria Mariano; Luigia Panariello; Dario Bianca; Giuseppe Monfrecola
Journal:  J Exp Clin Cancer Res       Date:  2012-05-28

3.  Benign dermoscopic parallel ridge pattern in plantar hyperpigmentation due to capecitabine.

Authors:  Linda Tognetti; Michele Fimiani; Pietro Rubegni
Journal:  Dermatol Pract Concept       Date:  2015-04-30

4.  Compound mucocutaneous adverse effects of oral capecitabine in a patient.

Authors:  Hyacinth Peter Pinto; Ramesh M Bhat; Dinesh Shet; Sukumar Dandekeri
Journal:  Indian Dermatol Online J       Date:  2014-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.